19 Oct 2022

Addressing the challenges of vaccine formulation

PDF 4.3 MB

To this day, our focus has been to successfully develop, manufacture and market high-quality adjuvants for our pharmaceutical customers. This heritage makes our vaccine adjuvants unique in the industry. A heritage we are proud of. 

Our industry-leading, Alhydrogel®, Adju-Phos® and Quil-A® are widely recognised in the vaccine industry for their unmatched track record when it comes to a proven history of safe and effective use.

Content provided by our supplier

Croda Europe Limited

  • GB
  • 2015
    On CPHI since
  • 2
  • 1000 - 4999
Company types
Primary activities
Excipients Manufacturer

Other Content from Croda Europe Limited (13)

  • Sponsored Content Croda: Solutions for Your High Value Drug Products

    Formulating a drug for parenteral delivery comes with its fair set of challenges. Aside from a high level of sensitivity to external factors like light and heat exposure, these large and complex drugs are prone to degradation when exposed to various chemical species.
  • Sponsored Content Avanti & Croda-Denmark: Advancing Vaccine Adjuvant Research

    Adjuvants. You’ve seen them on our website. You’ve seen them featured in our blog articles. Now we want to show you how Avanti’ & Croda-Denmark can enhance your vaccine adjuvant research!

    Keep reading to learn more!

  • Brochure Avanti cGMP Manufactured Lipids

    For over 40 years Avanti has provided API (Active Pharmaceutical Ingredient) Technology Development for Pharmaceutical and Biotechnology companies. Our unique reputation for quality in the development of pre-clinical and clinical candidates is well established. Our full range of services include process chemistry, scale-up manufacturing, supply chain management with analytical and regulatory requirements. Avanti’s experienced staff of chemists and lipid analysts are ready to meet your development needs with pre-clinical through phase III and commercial launch.
  • News Top 5 Industry Content Reads on CPHI Online This Month

    If you’re looking for news, product information and market trends from leading pharma companies, the Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner.

  • Brochure Croda Mill Hall press release

    Croda International Plc, the company that uses smart science to create high performance ingredients and technologies that improve lives, is excited to announce the expansion of its Mill Hall high purity excipients facility. This investment confirms Croda’s commitment to building its Life Sciences business and developing innovative pharmaceutical excipients, reinforcing Croda’s Purpose to use Smart science to improve lives™. With this latest Mill Hall expansion, Croda continues their ambitious target to become People Positive by 2030 by contributing to the successful development of 25% of WHO-listed pipeline vaccines.

    To find out more, please visit:
  • News Construction underway on new Croda North American HQ and Innovation Centre

    The facility will support the company'a goal of being climate, land and people positive by 2030.
  • Technical Data Polysorbates for Biopharma

    Super Refined™ Polysorbates for Biopharma applications.

    This document is relevant to the following market areas

    Health Care - DermaHealth Care - Pharma
    Health Care - Nutra
    Health Care - Animal Health

    This document is attached to the following products

    Super Refined™ Polysorbate 80
  • News Croda bolsters position in life sciences with the acquisition of Avanti Polar Lipids

    The transaction will more than double Croda’s R&D capability in drug delivery.
  • Technical Data Pharmaceutical excipients for ophthalmic formulations

    Pharmaceutical excipients for ophthalmic formulations.

    This document is relevant to the following market areas

    Health Care - Derma
    Health Care - Pharma
    Health Care - Nutra
    Health Care - Animal Health
  • News Croda commits to Science Based Targets for reduction of greenhouse gas emissions

    Group aiming to achieve a 50% reduction in absolute GHG emissions based on 2006 levels by 2030 and an 80% reduction by 2050.
  • Video Supporting the World's Biggest Challenges

    Smart Science to Improve Lives. For more than 75 years Croda Denmark has been dedicated to safe and effective adjuvants for use in both human and veterinary vaccines, as well as blood fractioning processes. We offer an experienced passionate team and personal interaction with comprehensive on-site advice and support anywhere in the world.
  • Webinar Formulation solutions for cannabinoids

    The use of cannabinoids (CBD) is a growing marketplace dominated by oral and topical formulations. Croda offers Super Refined™ formulation solutions providing benefits such as; improving stability and reducing taste impact. Find out more here: